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Abstract: A series of cyclic peptides, [(DipR)(WR)4 ], [(DipR)2 (WR)3 ], [(DipR)3 (WR)2 ], [(DipR)4 (WR)],
and [DipR]5 , and their linear counterparts containing arginine (R) as positively charged residues and
tryptophan (W) or diphenylalanine (Dip) as hydrophobic residues, were synthesized and evaluated
for their molecular transporter efficiency. The in vitro cytotoxicity of the synthesized peptides was
determined in human epithelial ovary adenocarcinoma cells (SK-OV-3), human lymphoblast peripheral blood cells (CCRF-CEM), human embryonic epithelial kidney healthy cells (HEK-293), human
epithelial mammary gland adenocarcinoma cells (MDA-MB-468), pig epithelial kidney normal cells
(LLC-PK1), and human epithelial fibroblast uterine sarcoma cells (MES-SA). A concentration of
5–10 µM and 3 h incubation were selected in uptake studies. The cellular uptake of a fluorescentlabeled phosphopeptide, stavudine, lamivudine, emtricitabine, and siRNA was determined in the
presence of peptides via flow cytometry. Among the peptides, [DipR]5 (10 µM) was found to be
the most efficient transporter and significantly improved the uptake of F’-GpYEEI, i.e., by approximately 130-fold after 3 h incubation in CCRF-CEM cells. Confocal microscopy further confirmed
the improved delivery of fluorescent-labeled [DipR]5 (F’-[K(DipR)5 ]) alone and F’-GpYEEI in the
presence of [DipR]5 in MDA-MB-231 cells. The uptake of fluorescent-labeled siRNA (F’-siRNA) in the
presence of [DipR]5 with N/P ratios of 10 and 20 was found to be 30- and 50-fold higher, respectively,
compared with the cells exposed to F’-siRNA alone. The presence of endocytosis inhibitors, i.e.,
nystatin, chlorpromazine, chloroquine, and methyl β-cyclodextrin, did not completely inhibit the
cellular uptake of F’-[K(DipR)5 ] alone or F’-GpYEEI in the presence of [DipR]5 , suggesting that a
combination of mechanisms contributes to uptake. Circular dichroism was utilized to determine the
secondary structure, while transmission electron microscopy was used to evaluate the particle sizes
and morphology of the peptides. The data suggest the remarkable membrane transporter property
of [DipR]5 for improving the delivery of various small molecules and cell-impermeable negatively
charged molecules (e.g., siRNA and phosphopeptide).
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1. Introduction
Cell-penetrating peptides (CPPs) are versatile systems for drug delivery due to their
ability to carry a wide range of molecules. CPPs are short peptides that facilitate the cellular
uptake of molecules ranging from small molecules to large fragments of DNA [1–4]. They
can be used in the context of direct peptide conjugation to the cargo through covalent
bonds or the incorporation into a multi-component delivery system via intermolecular
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hydrogen bonding, electrostatic, or hydrophobic interactions. Linear CPPs such as Tat
(trans-activator of transcription) [5,6], penetratin [7,8], and oligoarginine [9] have been
reported to efficiently enhance the cellular uptake of cargo molecules through different
mechanisms [10].
The truncated version of Tat has been used in a number of clinical trials; however,
to date, no approved therapy has used Tat [11]. One of the major challenges of Tat is
induced cerebrovascular toxicity and pro-inflammatory responses [12]. It has been reported
that excess hydrophobicity and/or positive charges such as polyarginine amino acids
can lead to membrane lysis at high doses of peptides [13]. To reduce the cytotoxicity, an
optimal number of arginine residues was reported to be approximately eight for an efficient
translocation [14]. Previous studies of CPPs by us and others indicated that an optimal
balance of positive charges and hydrophobicity is required for their interactions with the
cell membrane and the deep penetration into the lipid bilayer to increase the cellular uptake
safely and efficiently [15–23]. An optimal CPP can be used to improve the uptake of many
drugs with limited cell permeability, such as siRNA, highly hydrophobic compounds with
a limited solubility such as curcumin, and degradable drugs by proteases such as biologic
drugs [24].
A new class of cyclic CPPs containing alternating W and R residues ([WR]n ; n = 4, 5)
was previously reported, demonstrating diverse applications in the noncovalent and covalent drug delivery [25,26], improving the cellular uptake of phosphopeptides [27] and
oligonucleotides [28], generating peptide-capped gold nanoparticles (AuNPs) [29], silver
and selenium nanoparticles [30], and acting as surfactants and protein stabilizers [31]. These
peptides were used in conjugation with anticancer drugs such as doxorubicin [25,32–34],
camptothecin [35], and curcumin [36]. These studies concluded that large cyclic peptides
containing W and R residues [26,37] could be used as a molecular transporter of compounds.
In continuation of our efforts to design cyclic CPPs with improved molecular transporter properties, we report here the design and synthesis of a new class of CPPs, containing
R, diphenylalanine (Dip), and W residues (Figure 1), the evaluation of their cytotoxicity,
cellular uptake, nanostructure formation, and mechanism of actions. W and Dip have Log
P (partition coefficient) values of 1.82 and 2.93, respectively [38], indicating that Dip is more
hydrophobic than W. A number of W residues in [WR]5 [26,39] was replaced with Dip
residues to determine the effect of Dip on the cell penetration and the molecular transporter
capability of the peptides. The hypothesis was that by replacing W residues in [WR]5
with more hydrophobic Dip residues, peptides with more efficient cell-penetrating and
molecular transporter properties could be generated. Thus, [(DipR)(WR)4 ], [(DipR)2 (WR)3 ],
[(DipR)3 (WR)2 ], [(DipR)4 (WR)], and [DipR]5 peptides were synthesized along with five linear counterparts (Figure 1). The numbers of Dip and W residues were varied to determine
the optimal balance of hydrophobicity and hydrophilic residues for the maximum cellular
uptake. Previously, dipeptides with two phenylalanine amino acids have been reported as
an efficient siRNA delivery system with promising prospects for cancer therapy [40–48].
To the best of our knowledge, this is the first report of systematic design and evaluation
of CPPs containing R and Dip with or without W residues as molecular transporters. The
studies allowed us to determine whether there was a change in the molecular transporter
efficiency by replacing different numbers of W with Dip residues.
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All resins and protected
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AAPPTEC
(Louisville,
KY,(Louisville, KY,
USA). Fluorescent-labeled
antihuman immunodeficiency
virus (HIV)
drugs [20 ,30 -didehydroUSA). Fluorescent-labeled
antihuman immunodeficiency
virus (HIV) drugs
[2′,3′-didehy20 ,30 -dideoxythymidine
(stavudine,
20 ,30 -dideoxy-5-fluoro-30 -thiacytidine (emtricitabine,
dro-2′,3′-dideoxythymidine
(stavudine,
d4T),d4T),2′,3′-dideoxy-5-fluoro-3′-thiacytidine
(3TC)],
andand
fluorescent-labeled
phosphopeptide
(emtricitabine,FTC),
FTC),fluorescent-labeled
fluorescent-labeledlamivudine
lamivudine
(3TC)],
fluorescent-labeled
0 -GpYEEI) were prepared according to the previously reported procedures [37,49–52]. All
(F
phosphopeptide (F′-GpYEEI) were prepared according to the previously reported procedures [37,49–52]. All cell biology reagents were purchased from Wilken Scientific
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cell biology reagents were purchased from Wilken Scientific (Pawtucket, RI, USA) or Fisher
Scientific (Hanover Park, IL, USA). The final cyclic and linear peptides were characterized
by high-resolution matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)
(Bruker, GT 0264) from Bruker Inc. (Billerica, MA, USA). α-Cyano-4-hydroxycinnamic acid
was used as a matrix.
Human epithelial ovary adenocarcinoma cells (SK-OV-3, ATCC No. HTB-77), human
lymphoblast peripheral blood cells (CCRF-CEM, ATCC No. CCL-119), human embryonic
epithelial kidney healthy cells (HEK-293, ATCC No. CRL-1573), human epithelial mammary
gland adenocarcinoma cells (MDA-MB-468, ATCC No. HTB-132), pig epithelial kidney
normal cells (LLC-PK1, ATCC No. CL-101), and human epithelial fibroblast uterine sarcoma
cells (MES-SA, ATCC No. CRL-1976) were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). DAPI was used to stain the cell nuclei and was obtained
from Vector Laboratories (Burlingame, CA, USA). Cell Titer 96® AQueous MTS Reagent
was purchased from Promega (Madison, WI, USA). The circular dichroism analysis was
performed with a J-1500 Jasco spectrophotometer using nitrogen gas and PM-539 detector.
A peptide synthesizer (Tribute model, Protein Technologies, Inc., Tuscon, AZ, USA)
was used for automated peptide synthesis. All the crude peptides were purified using
reversed-phase high-performance liquid chromatography (RP-HPLC) from Shimadzu
(LC-20AP) (Canby, OR, USA) by using a gradient system of water and acetonitrile (ACN)
and were lyophilized. One of the analytical columns was Phenomenex 00G-4053-E0 Jupiter
C18, 5 µm particle size, 250 mm × 4.6 mm, and 300 Å pore size. The second analytical column
was Inertsil ODS-3 3U, Length 50 mm, and ID 4.6 mm. The preparative HPLC was LC-20AP
Prominence Preparative Liquid Chromatography Shimadzu HPLC. The preparative column
was 00G-4436-P0-AX Gemini Prep C18, 10 µm particle size, 250 mm × 21.2 mm, and 110 Å
pore size. In analytical and preparative HPLC systems, a gradient system of solvent A (99.9%
Millipore water with 0.1% TFA) and solvent B (99.9% ACN with 0.1% TFA) were used. The
final peptides had a purity of approximately ≥ 95% (Supplementary Information).
2.2. Synthesis of Peptides
The partially protected linear peptides (NH2 -W(Boc)-R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)-DipR(Pbf)-Dip-R(Pbf)-COOH), (NH2 -W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)-DipR(Pbf)-COOH), (NH2 -W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)COOH), (NH2 - W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-Dip-R(Pbf)COOH), and (NH2 -R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)-Dip-R(Pbf)-COOH) were
synthesized by using NH2 -Arg(Pbf)-trityl resin (0.572 mmol/g in 0.30 mmol scale) with an
automated peptide synthesizer or the manual synthesis. The side-chain-protected linear
peptides were synthesized by both automated and manual synthesis, as mentioned in the
manuscript. The cyclic peptides were all synthesized in the solution phase from side-chain
protected peptides after cleavage from the resin.
The resin was swelled in N,N-dimethylformamide (DMF) for 30 min. The solvent
was filtered. Three equivalents of the Fmoc-protected amino acids, Fmoc-3,3-diphenyl-Lalanine, Fmoc-L-Arg(Pbf)-OH, and Fmoc-Trp(Boc)-OH were used as the building blocks.
The coupling reactions were conducted in the presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU, 3 equiv.), N,N-diisopropylethylamine
(DIPEA, 6 equiv.), and DMF for 1 h at each step. The solvent was filtered, and the resin was
washed with DMF and dichloromethane (DCM) for about 5 min twice. Piperidine in DMF
(20% v/v, 15 mL, 2 × 15 min) was used for the Fmoc deprotection of the assembled amino
acids in each step. The solvent was filtered off, and the resin was washed, as described
above. The Kaiser test was utilized to ensure that each coupling reaction was completed.
The next amino acid was coupled with the same method.
For the synthesis of linear peptides, trifluoroacetic acid (TFA), anisole, thioanisole,
and dithiothreitol (DTT, 12,600 µL:700 µL:420 µL: 514 mg) were used to cleave the peptides
from the resin and to remove all the protecting groups. Cold diethyl ether (10 times the
amount of TFA) was added to peptides to precipitate followed by centrifuging as described
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previously [53], and the crude peptides were purified by using reverse-phase HPLC. Very
hydrophobic peptides may be dissolved in diethyl ether and may not get precipitated
completely. In those cases, the HPLC purification was conducted after evaporation of ether.
MALDI-TOF was used to confirm the molecular mass versus charge (m/z) the peptides.
Linear (W-R-Dip-R-Dip-R-Dip-R-Dip-R): MALDI-TOF (m/z) C101 H129 N29 O11 Calculated:
1878.3113, Found: 1879.3390 [M + H]+ ; Linear (W-R-W-R-Dip-R-Dip-R-Dip-R): MALDI-TOF
(m/z) C97 H126 N27 O11 Calculated: 1841.2503, Found: 1842.7980 [M + H]+ ; Linear (W-R-WR-W-R-Dip-R-Dip-R): MALDI-TOF (m/z) C93 H123 N28 O11 Calculated: 1804.1893, Found:
1805.7200 [M + H]+ ; Linear (W-R-W-R-W-R-W-R-Dip-R): MALDI-TOF (m/z) C89 H120 N29 O11
Calculated: 1767.1283, Found: 1768.5530 [M + H]+ ; Linear (R-Dip-R-Dip-R-Dip-R-Dip-R):
MALDI-TOF (m/z) C90 H119 N24 O10 Calculated: 1692.0973, Found: 1693.8660 [M + H]+
(Figures S1–S5, Supplementary Materials).
For the synthesis of cyclic peptides, protected assembled linear peptides were first
cleaved from the resin in the presence of DCM/trifluoroethanol (TFE)/acetic acid (AcOH)
(35 mL:10 mL:5 mL) while agitating for 3 h. The solvent was evaporated using a lowpressure setting after mixing with hexane and DCM to remove AcOH by forming an
azeotropic mixture. After adding 15 mL of DCM, enough hexane was added to make
the solution cloudy. Once the cloudy solution was formed, it was agitated to avoid any
precipitation. Next, the solvent was evaporated in a water bath with a temperature of 60 ◦ C.
The steps were repeated to get a homogeneous white powder with no clumps. MALDI-TOF
was used to confirm the molecular mass versus charge (m/z) of linear peptides. 1–2 µL
of each dissolved peptide with 50% ACN in water was applied on a steel plate (MTP 384
target plate ground steel BC, Bruker Daltonik, Bremen, Germany). Samples were dried by
placing them in an air current after mixing with 1 µL of the matrix solution (20 mg/mL of
α-cyano-4-hydroxycinnamic acid).
The side-chain protected linear peptides (0.3 mmol) were cyclized in the presence
of DMF (100 mL), DCM (25 mL), N,N-diisopropylcarbodiimide (DIC, 1.8 mmol, 279 µL),
and 1-hydroxy-7-azabenzotriazole (HOAt, 0.9 mmol, 122.5 mg) overnight. The solvents
were removed under low pressure. All the protecting groups were detached by mixing
the reaction mixture containing protected peptides with TFA, anisole, thioanisole, and
DTT (12,600 µL:700 µL:420 µL: 514 mg) for 3 h. The crude products were precipitated and
purified as described above.
Cyclic [Dip-R-W-R-Dip-R-Dip-R-Dip-R]: MALDI-TOF (m/z) C101 H127 N26 O10 Calculated:
1860.2963, Found: 1861.0360 [M + H]+ ; Cyclic [Dip-R-W-R-W-R-Dip-R-Dip-R]: MALDI-TOF
(m/z) C97 H124 N27 O10 Calculated: 1823.2353, Found: 1824.0460 [M + H]+ ; Cyclic [Dip-RW-R-W-R-W-R-Dip-R]: MALDI-TOF (m/z) C93 H121 N28 O10 Calculated: 1786.1743, Found:
1787.4050 [M + H]+ ; Cyclic [Dip-R-W-R-W-R-W-R-W-R]: MALDI-TOF (m/z) C89 H118 N29 O10
Calculated: 1749.1133, Found: 1750.6030 [M + H]+ ; Cyclic [Dip-R-Dip-R-Dip-R-Dip-R-DipR]: MALDI-TOF (m/z) C105 H130 N25 O10 Calculated: 1897.3573, Found: 1898.8040 [M + H]+
(Figures S6–S10, Supplementary Materials).
To synthesize fluorescent-labeled [KDipR]5 , F’-[K(DipR)5 ] (Figure S11, Supplementary
Materials), the sequence of the linear peptide was assembled on the resin using Fmoc solidphase methodology in the same manner as described above. An extra amino acid FmocL-Lys(Dde)-OH was coupled in the presence of HBTU (3 equiv.) and DIPEA (6 equiv.)
in DMF (10 mL). The last Fmoc was not deprotected, and 5(6)-carboxyfluorescein was
attached in the presence of HBTU (3 equiv.) and DIPEA (6 equiv.) in DMF (10 mL)
after removing Dde protecting group with hydrazine monohydrate (2% v/v) solution in
DMF (3 × 25 mL, each time 5 min) on the resin. As described before, piperidine in DMF
(20% v/v, 15 mL, 2 × 15 min) was used for the last Fmoc deprotection of the assembled
amino acid. The partially protected linear peptide was cleaved from the resin in the
presence of DCM/TFE/AcOH (35 mL:10 mL:5 mL) while agitating for 3 h. The side-chain
protected peptide (0.3 mmol) was cyclized in the presence of DMF (100 mL), DCM (25 mL),
DIC (1.8 mmol, 279 µL), and HOAt (0.9 mmol, 122.5 mg) overnight. The solvents were
removed under a low-pressure setting. All the protecting groups were detached by mixing

Cells 2022, 11, 1156

6 of 28

the reaction mixture containing protected peptides with TFA, anisole, thioanisole, and DTT
(12,600 µL:700 µL:420 µL: 514 mg) for 3 h. The crude product was precipitated and purified.
Q-TOF mass spectrometry was used to confirm the chemical structure of F’-[K(DipR)5 ].
Cyclic Fluorescent-labeled [K-Dip-R-Dip-R-Dip-R-Dip-R-Dip-R]: Q-TOF (m/z) C132 H152
N27 O17 Calculated: 2383.8373 Found: 2386.1892 [M + 3H]+ .
For HPLC purification, the crude peptides were dissolved in 50% of ACN in water and
passed through a filter or centrifuged to make sure the injected liquid was clear for injection.
The gradient elution was carried out using the mobile phase composition ranging from
95:5 water/ACN (v/v) to 5:95 water/ACN (v/v). The diode array detected the absorbance
of the amide bonds and aromatic rings at the given wavelength of 220 nm and 280 nm.
The HPLC solvents were delivered by pumps at a variable flow rate of 5 to 12 mL/min.
Representative analytical HPLC of compounds is shown in Figure S12. The mass spectra
determined the molecular mass versus charge (m/z) by using a positive reflective mode
of the MALDI mass spectrometer. The instrument MALDI-TOF Autoflex Speed (Bruker
Daltonik, Bremen, Germany) produced the final spectra.
2.3. In Vitro Cytotoxicity Assays
SK-OV-3, CCRF-CEM, HEK-293, MDA-MB-468, LLC-PK1, and MES-SA were used to
determine the cytotoxicity of the synthesized linear and cyclic peptides. About 5000, 10,000,
and 50,000 cells were seeded for SK-OV-3, HEK-293, and CCRF-CEM cells, respectively,
in 0.1 mL of medium per well of 96-well plates. An appropriate medium was used for
each cell line (SK-OV-3: McCoy’s 5A with L-glutamine containing fetal bovine serum
(FBS) (10%) and penicillin or streptomycin (1%); CCRF-CEM: RPMI-1640 medium with
L-glutamine and sodium bicarbonate containing FBS (10%) and penicillin or streptomycin
(1%); MDA-MB-468 cells: DMEM/F12 (1:1) (1×) with L-glutamine and 15 mM HEPES
containing FBS (10%) and penicillin or streptomycin (1%); LLC-PK1 cells: Dulbecco’s
Modified Eagle’s Medium with 4500 mg/L glucose, L-glutamine and sodium bicarbonate,
without sodium pyruvate liquid containing FBS (10%) and penicillin or streptomycin (1%);
MES-SA cells: consisting of half SK-OV-3 and half CCRF-CEM media; and HEK-293 cells:
Minimum Essential Medium Eagle with Earle’s salts and sodium bicarbonate, without
L-glutamine containing FBS (10%) and penicillin or streptomycin (1%)). Then, 20 µL of
peptides containing 5% DMSO in water were added to each well.
Adhesive cells were detached with 0.05% trypsin/EDTA after 15 min. The suspended
cells were seeded in the medium 24 h prior to the experiment according to the previously
reported procedure [26]. The medium was changed before adding the peptides for adherent
cells. Each concentration 5, 10, 25, 50, and 166 µM (containing 0.8% DMSO) had triplicate
wells to minimize possible errors. The plates were incubated for 24 h at 37 ◦ C in a humidified atmosphere of 5% CO2 . The cell viability was measured by utilizing Multi-Mode
Microplate Reader (SpectraMax M5 model, Molecular Devices, San Jose, CA, USA) after
adding 20 µL of the MTS reagent to each well and incubating for 3 additional hours. The
wavelength intensity at 490 nm showed the approximate number of live cells. The protocol
manager was selected “endpoint” on the spectrophotometer’s software (SoftMax Pro 7).
The 96-well plates were inserted inside spectrophotometer, and the data were acquired.
The percentage of cell viability was calculated using the following equation:


Average OD values of samples treated with the compound
=
∗ 100
(1)
Average OD values of no treatment samples
2.4. Cellular Uptake Studies
CCRF-CEM and SK-OV-3 cells were used to measure the cellular uptake of a fluorescentlabeled phosphopeptide (F’-GpYEEI) (2 µM), stavudine (F’-d4T) (2 µM) lamivudine (F’-3TC)
(1–2 µM), emtricitabine (F’-FTC) (2 µM), and siRNA (F’-siRNA) (36 nM) with the least toxic
concentration for each linear and the cyclic peptide (10 µM). The uptake was measured
in the presence and absence of the peptides. The SK-OV-3 (0.5 million) and CCRF-CEM
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(a million) cells were incubated in each well of 6-well plates with the synthesized peptide
and the fluorescent-labeled compound in one well. Another well contained the fluorescentlabeled compound alone for 3 h in an incubator (37 ◦ C in a humidified atmosphere of
5% CO2 ). The media did not contain FBS, and the final volume of each well was 2 mL.
Similar to the cytotoxicity study, adherent cells do not receive drugs right away, and a day
must pass to allow cells to attach to the surface. For more details, please refer back to the
cytotoxicity method described above.
The cells were transferred to FACS analysis tubes after being washed with phosphatebuffered saline (PBS). The cells were centrifuged 2500 RPM for 5 min with Fisher Scientific
accuSpin Micro 17 to precipitate the cells and to allow replacing the supernatant. The cells
were then vortexed with Nerl Blood Bank Saline pH 7–7.2 (flow cytometry buffer) and
transferred to the tube through a sterile cell strainer 40 µm Nylon Mesh. Finally, the cells
were resuspended in flow cytometry buffer and analyzed by flow cytometry (FACSVerse
model, Becton Dickinson, San Jose, CA, USA) using the FITC channel and the BD FACSuite
software. The device was washed before each experiment, and the flow rate was set at
medium. Finally, the cells were analyzed by using FITC channel 495 nm argon laser for the
excitation and the emitted 519 nm fluorescence for detection. The data presented was based
on the FITC-A mean intensity signal for 10,000 cells collected. All assays were performed
in triplicates. Results were evaluated to determine whether the peptides are facilitating the
fluorescence compound to cross the membrane.
2.5. Mechanism of Cellular Uptake of Cargo
To determine the mechanism of the cellular uptake, F’-[K(DipR)5 ] or the physical
mixture of the F’-GpYEEI and [DipR]5 were used to measure the fluorescence in the treated
CCRF-CEM cells. F’-[K(DipR)5 ] (5 or 10 µM) or the physical mixture of the F’-GpYEEI
(2 µM) and [DipR]5 (5 or 10 µM) were incubated with CCRF-CEM cells over 3 h. After each
incubation, the medium containing the peptide and cells was removed. The same protocol as
the cellular uptake study was used to prepare the cells as described above. Finally, the cells
were resuspended in the buffer and analyzed by flow cytometry using the FITC channel and
the BD FACSuite software. The data presented was based on the percentage of FITC-A mean
intensity signal for 10,000 cells collected. All assays were performed in triplicates.
A similar study was conducted in the presence of endocytosis inhibitors, such as
nystatin, chlorpromazine, chloroquine, and methyl β-cyclodextrin to determine whether
the uptake for F’-[K(DipR)5 ] or the fluorescent-labeled phosphopeptide in the presence
of [DipR]5 is endocytosis-dependent. The cells were preincubated by various inhibitors
including nystatin (50 µg/mL), chloroquine (100 µM), chlorpromazine (30 µM), and methylβ-cyclodextrin (2.5 mM) for 30 min. The cells were incubated with the physical mixture
of F’-GpYEEI and [DipR]5 (10 µM) or F’-[K(DipR)5 ] (10 µM) with an inhibitor for 3 h. The
flow cytometry study was performed as described above.
2.6. Circular Dichroism
Samples were prepared in 100 µM concentration dissolved in water only. The cuvette
with the 1 mm path length was used for all the measurements. The circular dichroism
analysis was performed with a J-1500 Jasco spectrophotometer using nitrogen gas and
PM-539 detector. Parameters were selected as follows: data interval 0.1 nm, data points
701, data pitch 0.1 nm, CD scale 200 mdeg/0.1 dOD, FL scale 200 mdeg/0.1 dOD, D.I.T 2 s,
bandwidth 1 nm, cell length 1 mm, start mode immediately, scanning mode continuous,
scanning speed 50 nm/min, shutter control auto, and N2 flowmeter manual. An average of
three readings between 190 and 260 nm were collected for each sample. The analysis was
carried out using one of Multivariate Regression Analyses, which is Principal Component
Regression (PCR) with a basis set containing 26 proteins reference under the following
conditions: standardization of result 100, replaced negative value to zero, and rejection
percentage of 1%.
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2.7. Transmission Electron Microscopy
Transmission electron microscopy (TEM) was done on a LVEM 5D Microscope model
(Delong instruments, Brno, Czech Republic) samples were prepared on an Ultrathin Carbon
Film on Lacey Carbon Support Film with 400 mesh copper from Ted Pella. Dilute solutions
of 30 µM concentration were used for the TEM analysis. Samples were dropped on
grids, evaporated overnight, and not stained. They were incubated for approximately
2 h after thawing from a freezer (0 to −18 ◦ C). Samples were air-dried, and images were
obtained with a LVEM5 (Delong Instruments, US) 5 keV field emission gun. The camera
was Zyla 5.5 Scientific CMOS with specifications of exposure 50–200 [ms], pixel readout
200 MHz—lowest noise, dynamic range 12-bit (low noise), and summing 1.
2.8. Dynamic Light Scattering
The samples were prepared in 10 µM concentration and were incubated for approximately 2 h after thawing from a freezer (0 to −18 ◦ C). Samples were analyzed by dynamic
light scattering (DLS) for particle sizes and the polydispersity index (PI). The data were
acquired by using a Zetasizer Nano ZS (Malvern, Worcestershire, UK), which has a 0.3 nm
to 10 µm particle size range and was equipped with a laser beam (λ = 633 nm; 4 mW) and a
scattered light detector positioned at an angle of 173◦ (noninvasive backscatter) in order
to unmask scattered light signals of low intensity originated by the smaller particles. The
analytical model was based on protein analysis. The sensitivity of the device is reported
to be at 0.1 mg/mL (lysozyme). The refractive index and absorption were set at 1.450
and 0.001 for the material. The refractive index, viscosity, and temperature were set at
1.33, 0.8872, and 25 ◦ C for dispersant. Particle sizes and PI measurements were made in
disposable cuvettes (ZEN0040) at 25 ◦ C and variable runs per measurement.
2.9. Confocal Microscopy
Coverslips were placed in a 6-well plate wells and covered with 2 mL of media.
Human epithelial mammary gland/breast adenocarcinoma cells (MDA-MB-231, ATCC No.
HTB-26) were used. 200,000 cells per well were seeded with DMEM media low glucose
(4 mM L-glutamine, 1000 mg/L glucose, and 110 mg/L sodium pyruvate) overnight on a
cover glass in 6-well plates. The cells were treated with the physical mixture of F’-GpYEEI
and [DipR]5 (10 µM) or F’-[K(DipR)5 ] in DMEM media low glucose without FBS and
incubated for 3 h at 37 ◦ C in a humidified atmosphere of 5% CO2 . Next, the media was
removed, and cells were washed three times with 2 mL PBS in each well. Cells were fixed
in 2 mL of 3.7% formaldehyde for 10 min and were washed 3 times in PBS (pH 7.6). 1 mL of
the Texas red solution was pipetted (40 µL of Texas Red and 100 mg BSA in 10 mL of PBS)
in each well to stay for 1 h at room temperature. The cells were washed at least 3 times
with 2 mL of PBS for 5 min. The nucleic staining with 13 µL of DAPI on each slide was
completed. Cells were covered with a coverslip carefully without air bubbles. The slide
dried horizontally overnight in a dark place that had airflow. The cells were photographed
and video recorded by using Nikon Instruments A1 Confocal Laser Microscope Series.
Operating the software NIS Elements version 4.3, the videos and images were captured
showing DAPI expressing as blue, Texas red expressing as red, and FITC expressing as
green. Images were taken by using lasers sequentially with a 60× objective lens. A drop of
oil was placed on slides. The scan mode was selected as Galvano. The scanning speed and
size were selected to be 5 frames/second and 1024 resolutions. Refractive index, pinhole
size, and numerical aperture were 1.51, 40.9 µm and 1.4, respectively.
A similar study was conducted in the presence of endocytosis inhibitors. The cells were
preincubated by various inhibitors including nystatin (50 µg/mL), chloroquine (100 µM),
chlorpromazine (30 µM), and methyl-β-cyclodextrin (2.5 mM) for 30 min. The cells were
incubated with F’-[K(DipR)5 ] (10 µM) and an inhibitor for 3 h. The confocal microscopy
images were taken using a widely used open-source image analysis tool, called Fiji software.
It can be downloaded at https://fiji.sc/ (accessed on 4 March 2022).
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2.10. Plasma Stability Study
The metabolic stability of [DipR]5 was assessed in human plasma by using a highresolution mass spectrometer (LC-QTOF-MS). To remove the background interference,
the data were processed by using a narrower (±0.1 m/z) extracted ion chromatogram
(EIC) window. Test compound (500 µM) was incubated in 25% human plasma in water
at 37 ◦ C. 50 µL aliquots were taken at different time points (0, 0.5, 1, 2, 3, and 13 h),
and the plasma proteins were precipitated by the addition of cold ethanol (50 µL) and
incubated for 5 min in ice and water. The samples were centrifuged at 7000 RPM for 5 min,
and the supernatant (10 µL) was injected into LC-QTOF-MS (Impact II model, Bruker
Daltonik, Bremen, Germany). The samples were analyzed on Waters Xterra MS C18 5 µm
2.10 mm × 50 mm column at a flow rate of 0.3 mL/min using a linear gradient of aqueous
ACN in the presence of formic acid (0.1%, v/v) as ion pair reagent. The analytes were
quantified by their peak areas of EIC. The percentage digestion of the test compound was
calculated relative to the peak areas at 0 min.
2.11. Data Analysis
The data are presented as the mean standard deviation for the stated number of samples.
A significant difference test was performed using One-way ANOVA (and nonparametric
or mixed), assuming equal SDs, assuming Gaussian distribution of residuals, corrected for
multiple comparisons using statistical hypothesis testing (Dunnett), and reported multiplicity
adjusted p-value for each comparison. Each p-value is adjusted to account for multiple
comparisons. The alpha threshold was set to 0.05 with 95% confidence interval.
3. Results and Discussion
Chemistry
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TFA, anisole, thioanisole, and DTT. For the synthesis of cyclic peptides, the protected
The synthesized peptides were evaluated for their cytotoxicity against selected canassembled peptides were cleaved from the resin first in the presence of a cleavage cocktail
cer and normal cell lines (Figures 3 and 4). Kidney cells (HEK-293 and LLC-PK1) are commonly used for the determination of cytotoxicity in normal cells to evaluate general toxicity in different organs. First, all cyclic and linear peptides were tested against SK-OV-3,
CCRF-CEM, and HEK-293 cells. SK-OV-3 and CCRF-CEM represent cancer cells, while
HEK-293 represents normal cells. SK-OV-3 are adherent cells, while CCRF-CEM are sus-
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containing DCM/TFE/AcOH while agitating for 3 h. The side-chain-protected linear
peptides were cyclized in the presence of DMF, DCM, DIC, and HOAt overnight. To
complete the synthesis of cyclic peptides, all protecting groups were removed, and the
peptides were cleaved from the resin in the presence of the cleavage cocktail of TFA, anisole,
thioanisole, and DTT.
The synthesis of the fluorescent-labeled [DipR]5 was accomplished using a similar
procedure except assembling an additional amino acid residue Fmoc-Lys(Dde)-OH before
cyclization. The Dde protecting group was removed in the presence of hydrazine monohydrate
in DMF. After coupling reaction with 5(6)-carboxyfluorescein in the presence of HBTU and
DIPEA, the Fmoc group was removed, and the cyclization was conducted as described
above (Figure S11, Supplementary Materials). Cold diethyl ether was added to precipitate
the crude peptide before centrifuging. All the peptides were purified using reversed-phase
HPLC and characterized by high-resolution MALDI-TOF mass spectrometry (Figures S1–S10,
Supplementary Materials) with about ≥95% purity.
3.2. Biological Activities
3.2.1. In Vitro Cytotoxicity Assays
The synthesized peptides were evaluated for their cytotoxicity against selected cancer
and normal cell lines (Figures 3 and 4). Kidney cells (HEK-293 and LLC-PK1) are commonly
used for the determination of cytotoxicity in normal cells to evaluate general toxicity in
different organs. First, all cyclic and linear peptides were tested against SK-OV-3, CCRF-CEM,
and HEK-293 cells. SK-OV-3 and CCRF-CEM represent cancer cells, while HEK-293 represents
normal cells. SK-OV-3 are adherent cells, while CCRF-CEM are suspended cells. Then,
the selected peptide, [DipR]5, was examined further against MDA-MB-468, LLC-PK1, and
MES-SA cells. MES-SA is a doxorubicin-resistant cell, while MDA-MB-468 is a triple-negative
breast cancer cell line. The data provided information about the potential application of the
peptides in different types of cancer cells.
In general, the replacement of Dip with W attenuated the cytotoxicity, as shown in
Figures 3 and 4. Cyclic [DipR]5 and linear R(DipR)4 significantly reduced the cell proliferation of CCRF-CEM by 64% and 63%, respectively, at a concentration of 25 µM while cyclic
[(DipR)(WR)4 ] decreased the cell proliferation by 47% and linear ((WR)4 (DipR)) did not show
any cytotoxicity at a concentration of 25 µM after 24 h incubation (Figure 3 ). The same pattern
was observed in SK-OV-3 and HEK-293 cells. Cyclic [DipR]5 and linear R(DipR)4 significantly reduced the cell proliferation of SK-OV-3 by 81% each, at a concentration of 25 µM
while cyclic [(DipR)(WR)4 ] and linear ((WR)4 (DipR)) decreased the cell proliferation by 76%
and 77%, respectively, after 24 h incubation (Figure 3). Cyclic [DipR]5 and linear R(DipR)4
significantly reduced the cell proliferation of HEK-293 by 56% and 63%, respectively, at
a concentration of 25 µM. In comparison, cyclic [(DipR)(WR)4 ] and linear ((WR)4 (DipR))
decreased the cell proliferation by 8% and 7%, respectively, after 24 h incubation (Figure 4).
The presence of a higher number of Dip residues in the peptide increased the cytotoxicity in CCRF-CEM cells. Cyclic [DipR]5 and linear R(DipR)4 significantly reduced the
cell proliferation of CCRF-CEM by 84% and 66%, respectively, at a concentration of 25 µM
while cyclic [(DipR)(WR)4 ] and linear ((WR)4 (DipR)) decreased the cell proliferation by
32% and 19%, respectively after 72 h incubation (Figure 3). The difference of incubation
between 24 h and 72 h in SK-OV-3 was not significant. Cyclic [DipR]5 and linear R(DipR)4
significantly reduced the cell proliferation of SK-OV-3 by 75% and 78%, respectively, at a
concentration of 10 µM while cyclic [(DipR)(WR)4 ] and linear ((WR)4 (DipR)) decreased the
cell proliferation by 40% and 10%, respectively, after 72 h incubation (Figure 3).
In general, the compounds were found to be more cytotoxic against SK-OV-3 cells
when compared with CCRF-CEM and HEK-293 cells. For example, cyclic [DipR]5 inhibited the cell proliferation of CCRF-CEM, SK-OV-3, and HEK-293 by 14%, 76%, and 6%,
respectively, at 10 µM and after 24 h incubation (Figures 3 and 4). The compounds were
found to be slightly selective against ovarian cancer cells at specific concentrations and
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incubation time. The cytotoxicity against normal cells (HEK-293) was significantly less
after 24 h incubation and specifically at 10 µM concentration.
The cytotoxicity of the cyclic peptides against CCRF-CEM and HEK-293 cells was
minimal at the concentration of 10 µM after 24 h incubation. For example, [DipR]5 inhibited
cell proliferation by 6% for HEK-293 cells and 14% for CCRF-CEM cells after 24 h incubation
at 10 µM concentration. The rest of the compounds showed minimal cytotoxicity at 10 µM
concentration in both cell lines.
[DipR]5 was selected for further cytotoxicity studies in MDA-MB-468, LLC-PK1, and
MES-SA cells to determine the concentration with minimal cytotoxicity for further studies.
Figure 5 shows that 10 µM concentration of [DipR]5 reduced the cell proliferation of MESCells 2022, 11, x FOR PEER REVIEW
11 of 31
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[DipR]5 was selected for further cytotoxicity studies in MDA-MB-468, LLC-PK1, and
MES-SA cells to determine the concentration with minimal cytotoxicity for further studies.
Figure 5 shows that 10 µM concentration of [DipR]5 reduced the cell proliferation of MESSA cells by 38% after 24 h incubation. However, no significant cytotoxicity was observed
against MDA-MB-468 and LLC-PK1 cells at 10 µM concentration after incubating 24 h and

Figure 5. Cytotoxicity study of [DipR]5 in MDA-MB-468, LLC-PK1, and MES- SA cells after 24 h (A)
Figure 5. Cytotoxicity study of [DipR]5 in MDA-MB-468, LLC-PK1, and MES- SA cells after 24 h (A)
and 72 h; (B) incubation. Results are mean ± SD (n = 3) (NS = not significant, *** p < 0.001 treatment
and 72 h; (B) incubation. Results are mean ± SD (n = 3) (NS = not significant, *** p < 0.001 treatment
vs. no treatment (NT)).
vs. no treatment (NT)).

The cytotoxicity of F’-[K(DipR)5] was also examined in CCRF-CEM cells at 3 h and 24
h incubations (Figure 6). At the highest concentration of 166 µM, no cytotoxicity was observed after 3 h incubation. On the other hand, F’-[K(DipR)5] inhibited cell proliferation
by 18% at 50 µM and 32% at 166 µM in CCRF-CEM cells after 24 h incubation. The data
clearly indicated that the F’-[K(DipR)5] causes minimal cytotoxicity at 10 µM concentration after 3 h and 24 h incubations.
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in
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by
approximately
7and
1.9-fold,
respectively,
after 3 h
increased the cellular uptake of F’-d4T (2 µM) in CCRF-CEM by 122 and 23-fold increase,
incubation
(Figure
7).
respectively, at a concentration of 10 µM while cyclic [(DipR)(WR)4] and linear
The flow
cytometry data for SK-OV-3 cells exhibited less uptake of fluorescence-labeled
((DipR)(WR)
4) increased the cell uptake of F’-d4T (2 µM) in CCRF-CEM by only 12 and
cargo
in
the
presence
of peptides
compared
with7).CCRF-CEM cells. For example,
10-fold increase, respectively,
after 3 when
h incubation
(Figure
[DipR]5 increased the cell uptake of F’-FTC (2 µM) in SK-OV-3 by 6-fold at a concentration
of 10 µM while it increased the cellular uptake of F’-FTC (2 µM) by 13-fold in CCRF-CEM

Cells 2022, 11, 1156

15 of 28

(Figures 7 and 8). CCRF-CEM are suspended cells, and SK-OV-3 are adherent cells. Thus,
these peptides could have fewer interactions with the adherent cells since they only interact
Cells 2022, 11, x FOR
PEER
with
oneREVIEW
side of the cells, and the other side is attached to the petri dish. SK-OV-3 cells also
are known to have an efflux mechanism and to pump foreign compounds [54].
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Figure 7. Cellular uptake of F’-GpYEEI (2 µM), F’-d4T (2 µM), F’-3TC (2 µM), and F’-FTC (2 µM) in
the presence of cyclic (A,C,E,G) and linear (B,D,F,H) peptides (10 µM) for CCRF-CEM cells after 3 h
incubation. Results are mean ± SD (n = 3) (* p < 0.05, ** p < 0.01, *** p < 0.001, NS = Not Significant).
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(Figure
7).
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F’-GpYEEI
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3 h incubation. On a side-by-side comparison of [R5K]W7A and [DipR]5, the data showed
presumably
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of
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[DipR]
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[DipR]5 had 5-fold higher cellular uptake of F’-GpYEEI under the same experimental5 conthe negatively
phosphopeptide.
There
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difference
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uptake
ditions
after 3 charged
h incubation
in CCRF-CEM
cells
(Figure
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compounds,
possibly
due
to
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interaction
of
[DipR]
with
5
proved the cellular uptake of F’-siRNA (36 nM) with N/P ratios of 10 and 20 by 30-fold
these
compounds.
and 50-fold, respectively when compared with siRNA alone in MDA-MB-231 cells after
Samara 9B).
et al.These
reported
cellular
[WR]
(10 µM) to
in deliver
the presence
of F’24 h (Figure
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that uptake
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GpYEEI
(2
µM)
increased
by
4-fold
[37].
We
have
previously
reported
[R
K]W
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peptide
5
7
charged phosphopeptides or oligonucleotides in the cancer cells.
as a cargo delivery system [33] that improved the delivery of F’-GpYEEI by 26-fold after
3 h incubation. On a side-by-side comparison of [R5 K]W7 A and [DipR]5 , the data showed
[DipR]5 had 5-fold higher cellular uptake of F’-GpYEEI under the same experimental
conditions after 3 h incubation in CCRF-CEM cells (Figure 9A). Furthermore, [DipR]5
improved the cellular uptake of F’-siRNA (36 nM) with N/P ratios of 10 and 20 by 30-fold
and 50-fold, respectively when compared with siRNA alone in MDA-MB-231 cells after
24 h (Figure 9B). These data reflect that [DipR]5 has the potential to deliver negatively
charged phosphopeptides or oligonucleotides in the cancer cells.
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We also examined the cellular uptake of F’-[K(DipR)5 ] at different concentrations
(10 µM and 5 µM). The uptake of F’-[K(DipR)5 ] showed slight concentration dependence
uptake. The uptake of F’-[K(DipR)5 ] (10 and 5 µM) have values of 179 and 154-fold increase
for 10 and 5 µM within 3 h, respectively, as compared to F’-GpYEEI (2 µM) (Figure 10B).
To explore the cellular uptake mechanism of action, another study was conducted
in the presence of endocytosis inhibitors such as nystatin, chlorpromazine, chloroquine,
and methyl β-cyclodextrin to determine whether the cellular uptake of F’-[K(DipR)5 ] alone
and F’-GpYEEI in the presence of [DipR]5 were endocytosis-dependent. None of the
endocytosis inhibitors completely inhibited the cellular uptake. Chloroquine and nystatin
reduced slightly 1.9–1.3-fold the uptake of F’-GpYEEI (2 µM) in the presence of [DipR]5
(10 µM) (Figure 11A). Likewise, endocytosis inhibitors chloroquine and nystatin reduced
the cellular uptake of F’-[K(DipR)5 ] (10 µM) slightly by 1.3 and 1.5-fold, respectively
(Figure 11B). The results suggest that a combination of multifaceted mechanisms could
contribute to the uptake of F’-[K(DipR)5 ] alone and F’-GpYEEI in the presence of [DipR]5
across the plasma membrane.

Cells 2022, 11, 1156 Cells 2022, 11, x FOR PEER REVIEW

450

700

***
***

600
Mean Fluorescence Intensity (A.U.)

Mean Fluorescence Intensity (A.U.)

400

19 of 28

350
300
250
10 µM

200

5 µM
150

***
***
500

400
10 µM
300

5 µM

200

100
100

50

0

0

(A)

(B)

10.uptake
(A) The
cellular
uptake study
of F’-GpYEEI
(2 µM)
the presence
[DipR]5 (5 or
Figure 10. (A) TheFigure
cellular
study
of F’-GpYEEI
(2 µM)
in the presence
of in
[DipR]
5 (5 or 10ofµM)
5
]
(5
or
10
µM)
in CCRF-CE
in
CCRF-CEM
cells
and
(B)
the
cellular
uptake
of
F’-[K(DipR)
in CCRF-CEM cells and (B) the cellular uptake of F’-[K(DipR)5 ] (5 or 10 µM) in CCRF-CEM cells after
Cells 2022, 11, x FOR PEER REVIEW
22 of 31
after
3
h
incubation.
Results
are
mean
±
SD
(n
=
3)
(***
p
<
0.001).
3 h incubation. Results are mean ± SD (n = 3) (*** p < 0.001).

Mean Fluorescence Intensity (A.U.)

600
500
400
300
200
100
0

We also examined the cellular uptake of F’-[K(DipR)5] at different concentrati
*** and 5 µM). The uptake of F’-[K(DipR)5] showed slight concentration depende
µM
***
***
take. The uptake of F’-[K(DipR)
***5] (10 and 5 µM) have values of 179 and 154-fold i
for 10 and 5 µM within 3 h, respectively, as compared to F’-GpYEEI (2 µM) (Figur
To explore the cellular uptake mechanism of action, another study was condu
the presence of endocytosis inhibitors such as nystatin, chlorpromazine, chloroqui
methyl β-cyclodextrin to determine whether the cellular uptake of F’-[K(DipR)5] alo
F’-GpYEEI in the presence of [DipR]5 were endocytosis-dependent. None of the e
tosis inhibitors completely inhibited the cellular uptake. Chloroquine and nysta
duced slightly 1.9–1.3-fold the uptake of F’-GpYEEI (2 µM) in the presence of [Dip
µM) (Figure 11A). Likewise, endocytosis inhibitors chloroquine and nystatin redu
cellular uptake of F’-[K(DipR)5] (10 µM) slightly by 1.3 and 1.5-fold, respectively
11B). The results suggest that a combination of multifaceted mechanisms could con
to the uptake of F’-[K(DipR)5] alone and F’-GpYEEI in the presence of [DipR]5 acr
plasma membrane.

(A)
800

nce Intensity (A.U.)

Figure 11. Cont.
700
600
500
400

***

***

***

***

Cells 2022, 11, 1156

20 of 28

(A)
Mean Fluorescence Intensity (A.U.)

800

***

***

700

***

***

600
500
400
300
200
100
0

(B)

Figure
11. (A)
The cellular
uptake
study of
µM) in the
presence
of [DipR]
Figure 11. (A) The
cellular
uptake
study of
F’-GpYEEI
(2F’-GpYEEI
µM) in the(2presence
of [DipR]
µM) 5 (10 µM
5 (10
in CCRF-CEM
after 3 h incubation.
(B) The
cellular
study
and endocytosisendocytosis
inhibitors ininhibitors
CCRF-CEM
cells after 3 cells
h incubation.
(B) The cellular
uptake
studyuptake
of
[K(DipR)
5] (10 µM) and endocytosis inhibitors in CCRF-CEM cells after 3 h incubation. Resu
F’-[K(DipR)5 ] (10
µM) and
endocytosis inhibitors in CCRF-CEM cells after 3 h incubation. Results are
mean ± SD (n = 3) (*** p < 0.001).
mean ± SD (n = 3) (*** p < 0.001).

Circular Dichroism
3.2.4. Circular3.2.4.
Dichroism

The secondaryThe
structures
of all
peptidesofwere
investigated
circular dichroism
secondary
structures
all peptides
werewith
investigated
with circular dich
spectroscopy to
determine whether
there was
any correlation
the secondary
struc-the secon
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to determine
whether
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tures of the peptides and their molecular transporter properties. Figure S13 (Supplementary
Materials) shows the CD spectra of peptides at 100 µM in water. In general, an α-helix
structure gives rise to two negative bands at 222 and 208 nm of almost equal intensities
and a strong positive band at about 193 nm. The highest percentage of α-helix structure for
[(DipR)(WR)4 ] and ((WR)(DipR)4 ) with values 28.9% and 29.8%, respectively, were detected
(Table S1, Supplementary Materials). The β-sheet structure exhibits a negative band at
218 nm and a positive band at 195 nm [55]. The highest values for the β-sheet structure
were detected for R(DipR)4 and ((WR)2 (DipR)3 ) with values 36.5% and 38.0%, respectively
(Table S1, Supplementary Materials). [DipR]5 showed mostly a random coil formation
(49.9%) with a negative band near 195 nm (Figure S13A, Supplementary Materials). [DipR]5
was the most effective transporter and did not exhibit any distinct structure. Thus, there
was no correlation between the secondary structure of peptides and their molecular transporter properties. The cargo transporter property of [DipR]5 is presumably related to the
nature of the interactions of this peptide with cargo molecules and the phospholipid bilayer.
3.2.5. Transmission Electron Microscopy
CPPs can self-assemble and generate various types of nanoparticles (NPs) such as
spherical or oval morphology [56]. Raymond et al. reported self-assembling β-sheet peptide
(QW)6 attached to ten lysine residues (K10) to form persistent 50 nm β-sheet nanofibrils
nanoparticles [57]. We examined the self-assembling tendency of a number of peptides
using transmission electron microscopy (TEM) images.
[(DipR)(WR)4 ] with the highest numbers of tryptophan residues showed a nanofiber
structure with an approximate diameter of 50 nm (Figure 12). These nanofibers are com-
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posed of a distorted β-sheet and α-helix secondary structure, as observed in the CD
spectrum (Table S1, Supplementary Materials). R(DipR)4 (Figure 12) and [(DipR)2 (WR)3 ]
(Figure S14, Supplementary Materials) showed star-shaped particles, while [DipR]5 showed
an aggregation and nanoparticle sizes of around ≤30 nm (Figure 12). The data suggest
increasing the number of diphenylalanine residues could lead to more self-assembly and
aggregation. Star-like structures with an approximate size of 1000–2000 nm indicate the
formation of a random network, such as nonclassic coacervates reported in the literature
through the interaction between positive charges and the aromatic π-system [58].
There was no correlation between the morphology of the peptides and their cellular
uptake properties. For TEM, a concentration of 30 µm was used on grids and evaporated
overnight. The longer time and higher concentration allow the peptide to self-assemble and
generate different structures or larger particles. For cellular uptake studies, a concentration
of 10 µM and incubation time of 3 h were used with a cargo molecule. We did not study
the morphology of the peptide under the same conditions. However, our earlier work has
shown that large size particles are formed with longer incubation time and at a higher
Cells 2022, 11, x FOR PEER REVIEWconcentration. We expect the morphology of the peptide to be different in the presence
24 of 31of
cargo and under the conditions used in uptake studies.
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S15, Supplementary Materials). The particle formation was confirmed, as shown in TEM
images for [DipR]5 .
3.2.7. Confocal Microscopy
Confocal microscopy was used to determine the localization of the molecular cargo
in the presence of [DipR]5 within the cells. MDA-MB-231 cells were seeded and treated
with F’-[K(DipR)5 ] (10 µM) alone and [DipR]5 (10 µM) in the presence of F’-GpYEEI (2 µM)
and then incubated for 3 h at 37 ◦ C. The cellular uptake was monitored with confocal
microscopy. The top panel of Figure 13 shows the control cells treated with F’-GpYEEI
alone, demonstrating the very low uptake. On the lower panel of Figure 13, the confocal
image of F’-GpYEEI in the presence of [DipR]5 is shown. A higher cellular uptake and
higher intensity of the fluorescent-labeled phosphopeptide (green color) were observed in
the presence of [DipR]5 . F’-GpYEEI was mostly localized in the cytosol. In addition, a 3D
video and every half micrometer image of the cells can be watched by accessing the links
(Supplementary Materials) (watch the videos in 720 p quality or higher). The data suggests
the efficient cytosolic delivery of F0 -GpYEEI in the presence of [DipR]5, and this delivery
system can be beneficial for the delivery of cargos such as siRNA and phosphopeptide to
the cytoplasm.
To determine the location of CPPs, the uptake of F’-[K(DipR)5 ] was monitored by
confocal microscopy (Figure 14). The top panel shows the control cells without any treatments and any significant green fluorescence color. The confocal images of cells treated
with F’-[K(DipR)5 ] are shown on the lower panel. A higher cellular uptake and higher
intensity of F’-[K(DipR)5 ] (green color) were observed. F’-[K(DipR)5 ] was mostly localized
in the cytosol. In addition, a 3D video and every half micrometer image of the cells can
be watched by accessing the links (Supplementary Materials) (watch the videos in 720 p
quality or higher).
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As described in flow cytometry studies above, the uptake of F’-[K(DipR)5 ] was not
completely blocked by endocytosis inhibitors. The confocal microscopy studies of F’[K(DipR)5 ] was conducted in the presence of endocytosis inhibitors, which are nystatin,
methyl-β-cyclodextrin, chloroquine, and chlorpromazine to confirm the data (Figure 15).
Change of concentrations did not change the intensity of the green color significantly
(Figure S16, Supplementary Materials). The data are consistent with flow cytometry
studies. Chlorpromazine reduced the uptake slightly. The drug is an inhibitor of clathrinmediated endocytosis by preventing the assembly and disassembly of clathrin lattices on
cell surfaces and on endosomes [59]. Nystatin and chloroquine inhibit caveolae-mediated
endocytosis and clathrin-dependent endocytosis, respectively. Thus, a combination of
uptake mechanisms contributes to the uptake of F’-[K(DipR)5 ] across the membrane.
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15% degradation of [DipR]5 was observed after 1 h. However, degradation slowed down at
the 2 h time point. The results clearly indicate the high stability of the peptide, possibly
due to the presence of unnatural amino acids and the cyclic nature of the peptide.
4. Conclusions
[DipR]5 was discovered as a novel CPP and molecular transporter of small and large
cargo molecules. Ten linear and cyclic peptides containing R, W, and Dip were synthesized
and evaluated for their molecular transporter properties. The difference in the number of
unnatural amino acids and their linear or cyclic structures provided adequate structural
diversity for the study of cellular uptake. Cellular uptake studies were conducted at 10 µM
and incubation for 3 h by flow cytometry and confocal microscopy techniques. Among
the peptides, [DipR]5 significantly improved the cellular uptake of F’-GpYEEI, F’-siRNA,
F’-3TC, and F’-FTC when compared with cells exposed to cargo alone. Confocal microscopy
demonstrated the delivery of F’-[K(DipR)5 ] alone and F’-GpYEEI in the presence of [DipR]5 ,
localizing mostly in the cytosol. Endocytosis inhibitors did not completely inhibit the
uptake of these molecules, indicating a contribution of a combination of mechanisms in the
uptake. Thus, [DipR]5 may have broad applications as an efficient CPP and a molecular
transporter agent.
Supplementary Materials: Supplementary data to this article can be found online via https://www.
mdpi.com/article/10.3390/cells11071156/s1 and provides MALDI-TOF spectra of the peptides,
analytical HPLC methods, chromatography spectra of peptides, synthetic Scheme for F’-[K(DipR)5 ],
circular dichroism spectra, tabulated CD data, videos of cellular uptake, transmission electron
microscopy images of [(DipR)2 (WR)3 ], dynamic light scattering of [DipR]5 , plasma stability of [DipR]5 ,
and confocal microscopy images of F’-[K(DipR)5 ] treated with different concentrations of endocytosis
inhibitors. Table S1. Estimate of peptide secondary structures; Figure S1. Linear (W-R-Dip-R-Dip-RDip-R-Dip-R): MALDI-TOF (m/z) C101 H129 N29 O11 Calculated: 1878.3113 Found: 1879.3390 [M + H]+ ;
Figure S2. Linear (W-R-W-R-Dip-R-Dip-R-Dip-R): MALDI-TOF (m/z) C97 H126 N27 O11 Calculated:
1841.2503 Found: 1842.7980 [M + H]+ ; Figure S3. Linear (W-R-W-R-W-R-Dip-R-Dip-R): MALDI-TOF
(m/z) C93 H123 N28 O11 Calculated: 1804.1893 Found: 1805.7200 [M + H]+ ; Figure S4. Linear (W-RW-R-W-R-W-R-Dip-R): MALDI-TOF (m/z) C89 H120 N29 O11 Calculated: 1767.1283 Found: 1768.5530
[M + H]+ ; Figure S5. Linear (R-Dip-R-Dip-R-Dip-R-Dip-R): MALDI-TOF (m/z) C90 H119 N24 O10
Calculated: 1692.0973 Found: 1693.8660 [M + H]+ ; Figure S6. Cyclic [Dip-R-W-R-Dip-R-Dip-R-Dip-R]:
MALDI-TOF (m/z) C101 H127 N26 O10 Calculated: 1860.2963 Found: 1861.0360 [M + H]+ ; Figure S7.
Cyclic [Dip-R-W-R-W-R-Dip-R-Dip-R]: MALDI-TOF (m/z) C97 H124 N27 O10 Calculated: 1823.2353
Found: 1824.0460 [M + H]+ ; Figure S8. Cyclic [Dip-R-W-R-W-R-W-R-Dip-R]: MALDI-TOF (m/z)
C93 H121 N28 O10 Calculated: 1786.1743 Found: 1787.4050 [M + H]+ ; Figure S9. Cyclic [Dip-R-W-RW-R-W-R-W-R]: MALDI-TOF (m/z) C89 H118 N29 O10 Calculated: 1749.1133 Found: 1750.6030 [M
+ H]+ ; Figure S10. Cyclic [Dip-R-Dip-R-Dip-R-Dip-R-Dip-R]: MALDI-TOF (m/z) C105 H130 N25 O10
Calculated: 1897.3573 Found: 1898.8040 [M + H]+ ; Figure S11. Synthesis of Fluorescence-labeled
[K(DipR)5 ]; Figure S12. Chromatography Spectra of peptides; Figure S13. Circular dichroism
spectra of (A) [DipR]5 ; (B) [(DipR)4 (WR)]; (C) [(DipR)3 (WR)2 ]; (D) [(DipR)2 (WR)3 ]; (E) [(DipR)(WR)4 ];
(F) R(DipR)4 ; (G) ((WR)(DipR)4 ); (H) ((WR)2 (DipR)3 ); (I) ((WR)3 (DipR)2 ); (J) ((WR)4 DipR)) were
conducted using 100 µM peptide concentration; Figure S14. Transmission electron microscopy image
of [(DipR)2 (WR)3 ]; Figure S15. Dynamic light scattering of [DipR]5 (10.0 µM), Z Average 200.6, PI
0.359; Figure S16. Confocal microscopy images of F’-[K(DipR)5 ] (10 and 20 µM) in the presence of
chloroquine (100 and 50 µM) or chlorpromazine (30 and 15 µM), in MDA-MB-231 cells after 3 h
incubation; Figure S17. The plasma stability of [DipR]5 chromatograms; Figure S18. The plasma
stability of [DipR]5 .
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